MedInfo World

Empowering patients through shared knowledge and community-driven health insights.

Platform

Drug Information
Health Conditions
Active Ingredients

Support

Help Center
Terms of Use
Privacy Policy
Disclaimer

Company

About Us
Contact

Medical Disclaimer

The information on this website is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Terms Privacy Disclaimer

Relatlimab – Uses, Side Effects, Dosage & Drug Information | MedInfo World | MedInfo World

Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.

Home Active IngredientsRelatlimab

Relatlimab

Programmed Death Receptor-1 Blocking Antibody [EPC]

1 Drug1 Variant

Clinical Data

Name

Relatlimab

Raw Name

RELATLIMAB

Drug Classes

Programmed Death Receptor-1 Blocking Antibody [EPC]Lymphocyte Activation Gene-3 Blocker [EPC]

Important Notice

This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Relatlimab.

Mechanism of Action

Programmed Death Receptor-1-directed Antibody Interactions [MoA]Lymphocyte Activation Gene-3 Antagonists [MoA]

Identifiers

RxCUI

2596778, 2596784

UNII

31YO63LBSN, AF75XOF6W3